TraceLink Inc. has closed a $93 million investment round led by Georgian Partners, with new investors Vulcan Capital and Willett Advisors LLC, and participation by all existing investors: FirstMark Capital, Volition Capital, F-Prime Capital and Goldman Sachs. TraceLink has also announced that Tyson Baber from Georgian Partners has joined its Board of Directors. Since its founding in 2009, TraceLink has…
Serialization Survey Reveals ‘Massive Gap’ In Industry Readiness
TraceLink Inc. released its second annual Global Drug Supply, Safety and Traceability report, including results from 660 respondents across the pharmaceutical supply chain—the largest survey conducted on pharmaceutical track and trace. The report highlights a massive gap in industry readiness for drug serialization, with only one-third of respondents stating that they are “very prepared” to comply with serialization deadlines…
Pharma Execs See End-to-End Product Visibility Achievable in Five Years
NEXUS 17 attendees cite information sharing as largest benefit from end-to-end visibility. TraceLink Inc., a global track and trace network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, announced new industry findings from its annual conference, NEXUS 17. Interactive polling results indicated that the majority of pharmaceutical supply…
